Outside of HD, no clear consensus on testing for suspected genetic forms of dementia emerged from the CPGs, with advice ranging from “genetic testing are not indicated for routine diagnostic testing” from the Swiss Academy of Medical Sciences (SAMS) guideline (Swiss Academy of Medical Sciences, 2018) to “if the clinical diagnosis is that of frontotemporal dementia, genetic testing for mutations in progranulin (PGRN) and microtubule-associated protein tau (MAPT) is clearly indicated” in the EFNS guideline from 2010 (Burgunder et al., 2010). This evidence concerns the gene MAPT and Huntington disease.